ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.720,01
-1,47%
S&P 500
5.702,55
-0,19%
Dow Jones
42.063,36
0,09%
Euro vs US Dollar
1,11705
0,00%
Bitcoin
63.215,92
-0,25%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Oragenics Inc (OGEN)

  7. Oragenics Inc (OGEN) News

OGEN

Oragenics (OGEN)

Oragenics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:OGEN
DatumZeitQuelleÜberschriftSymbolFirma
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
21/09/202403h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
20/09/202422h11Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
11/09/202413h45Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsAMEX:OGENOragenics Inc
05/09/202422h45Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
05/09/202422h30GlobeNewswire Inc.Oragenics, Inc. Announces Closing of Public OfferingAMEX:OGENOragenics Inc
05/09/202414h26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:OGENOragenics Inc
04/09/202414h36GlobeNewswire Inc.Oragenics, Inc. Announces Pricing of Public OfferingAMEX:OGENOragenics Inc
04/09/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:OGENOragenics Inc
03/09/202422h06Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]AMEX:OGENOragenics Inc
21/08/202414h45GlobeNewswire Inc.Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed PatientsAMEX:OGENOragenics Inc
21/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
16/08/202422h45Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933AMEX:OGENOragenics Inc
16/08/202422h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
16/08/202422h30GlobeNewswire Inc.Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing StandardsAMEX:OGENOragenics Inc
14/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
14/08/202414h30GlobeNewswire Inc.Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature RangeAMEX:OGENOragenics Inc
12/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
12/08/202414h30GlobeNewswire Inc.Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity StudyAMEX:OGENOragenics Inc
09/08/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OGENOragenics Inc
08/08/202414h45GlobeNewswire Inc.Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity TestingAMEX:OGENOragenics Inc
08/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
22/07/202422h05Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
10/07/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
 Showing the most relevant articles for your search:AMEX:OGEN

Kürzlich von Ihnen besucht

TG
A2RYQA
Colgate Palmolive
LSE
QPP
Quindell
USOTC
RENI
Resilient Energy (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten